Clinical Trial Update: Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of pemetrexed (Alimta) in patients with head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 1 | Status: COMPLETED